CTOs on the Move


 
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.indiva.com
  • 1050 Hargrieve Drive Unit 10
    London, ON CAN N6E 1P5
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Indiva raised $14M on 10/16/2019
Indiva raised $11M on 02/16/2021

Similar Companies

Attain ABA

Attain ABA Therapy provides quality ABA therapy to children with autism. Our experienced BCBAs will create a customized treatment plan tailored to YOUR childs needs. Enroll Today!

BHE

BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.

PharmaDerm

PharmaDerm is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.

Pliant Therapeutics

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.